TY - JOUR
T1 - Factors to guide the use of extended-release buprenorphine formulations for specific patient populations
AU - Cuperfain, Ari B.
AU - Katznelson, Gali
AU - Costa, Tianna
AU - Wong, Patrick
AU - Beyraghi, Narges
AU - George, Tony P.
AU - Lofwall, Michelle R.
AU - Chopra, Nitin
N1 - Publisher Copyright:
© 2023 Taylor & Francis Group, LLC.
PY - 2024
Y1 - 2024
N2 - Background: Opioid agonist therapy is first line in the management of opioid use disorder (OUD). Many guidelines support buprenorphine as the optimal treatment due to its preferred safety profile. Extended-release buprenorphine (BUP-XR) is a weekly or monthly subcutaneously administered formulation of buprenorphine. Emerging research has explored the use of BUP-XR in a variety of patient populations to guide clinicians in determining which patients may or may not benefit from BUP-XR. Methods: We conducted a literature review in Medline, PsycInfo and Embase to capture the literature to date on BUP-XR. Abstracts were reviewed, and papers which guided selection of individuals who would or would not benefit from BUP-XR were included. Results: Our search returned 359 articles, and 31 met inclusion criteria. Special populations who may benefit from BUP-XR include individuals experiencing homelessness, incarceration, and medical or psychiatric comorbidity, while caution should be used around pregnancy. Patient preference and patient-centered outcomes were recurring considerations to guide the selection of BUP-XR. Conclusions: Extended-release buprenorphine formulations represent a relatively new tool for managing OUD and may specifically benefit patients undergoing transitions in care. Further research on the comparative effectiveness of extended-release versus daily-dosing formulations and in other populations of interest is needed.
AB - Background: Opioid agonist therapy is first line in the management of opioid use disorder (OUD). Many guidelines support buprenorphine as the optimal treatment due to its preferred safety profile. Extended-release buprenorphine (BUP-XR) is a weekly or monthly subcutaneously administered formulation of buprenorphine. Emerging research has explored the use of BUP-XR in a variety of patient populations to guide clinicians in determining which patients may or may not benefit from BUP-XR. Methods: We conducted a literature review in Medline, PsycInfo and Embase to capture the literature to date on BUP-XR. Abstracts were reviewed, and papers which guided selection of individuals who would or would not benefit from BUP-XR were included. Results: Our search returned 359 articles, and 31 met inclusion criteria. Special populations who may benefit from BUP-XR include individuals experiencing homelessness, incarceration, and medical or psychiatric comorbidity, while caution should be used around pregnancy. Patient preference and patient-centered outcomes were recurring considerations to guide the selection of BUP-XR. Conclusions: Extended-release buprenorphine formulations represent a relatively new tool for managing OUD and may specifically benefit patients undergoing transitions in care. Further research on the comparative effectiveness of extended-release versus daily-dosing formulations and in other populations of interest is needed.
KW - Opioids
KW - buprenorphine
KW - depot
KW - opioid use disorder
KW - special populations
UR - http://www.scopus.com/inward/record.url?scp=85147671644&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85147671644&partnerID=8YFLogxK
U2 - 10.1080/14659891.2023.2174908
DO - 10.1080/14659891.2023.2174908
M3 - Review article
AN - SCOPUS:85147671644
SN - 1465-9891
VL - 29
SP - 340
EP - 346
JO - Journal of Substance Use
JF - Journal of Substance Use
IS - 3
ER -